<DOC>
	<DOCNO>NCT02954263</DOCNO>
	<brief_summary>Multiple ascend dose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics TD-1439 healthy adult elderly subject</brief_summary>
	<brief_title>Multiple Ascending Dose Study TD-1439 Healthy Adult Elderly Subjects</brief_title>
	<detailed_description />
	<criteria>Body Mass Index ( BMI ) 18 32 kg/m2 inclusive Women child bear potential must negative pregnancy test either abstain sex use highly effective method birth control Women nonchildbearing potential least 2 year postmenopausal surgically sterile Males must abstain sex use highly effective method birth control Negative HIV , Hepatitis A , B , C Female subject pregnant , lactating , breastfeed plan become pregnant study . Subjects history angioedema . Subject evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . Subject acute illness ( gastrointestinal , infection [ e.g. , influenza ] known inflammatory process ) Subject bradycardia Subject hypertension Subjects orthostatic hypotension Subjects orthostatic tachycardia Subject know personal family history congenital long QT syndrome know family history sudden death . Subject donate blood blood component blood loss exceed 400 mL within 90 day prior Screening . Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple ascend dose ( MAD )</keyword>
</DOC>